Accordingly, recent work indicated that mutant EGFR induces resistance to irreversible EGFR inhibitors in NSCLC through the activation of IL-6 receptor/JAK1/STAT3 signaling [58]. The gene discussed is JAK1; the disease is non-small cell lung carcinoma.